

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: Sienna Cancer Diagnostics Ltd

主要联系人姓名: Matthew Hoskin

主要联系人职务: 首席运营官

公司网址: www.siennadiagnostics.com.au

公司地址: c/o Small Technologies Cluster, 1 Dalmore Drive, Scoresby VIC 3179

公司未上市

公司简介

Sienna 是一家位于澳大利亚墨尔本的生物科技公司。Sienna 依托其在全球临床领域的庞大网络, 推动了多种针对癌症的新式体外诊断产品(IVD)的研发。Sienna 也为科研机构 and 病理化验室生产单独的组件产品, 以供科研使用或是用于其内部自行研发测试。2014 年, Sienna 具有丰富经验和多元化的团队负责在美国推出了其第一款产品: 抗人源端粒酶逆转录酶抗体 (SCD-A7)。

Sienna 计划将其技术销往全球, 并以北美洲、欧洲、亚太地区作为主要进军市场。Sienna 公司将在不同国家内利用直销搭配技术支持人员并安排分销合作伙伴的方式销售产品。

关键技术或领先技术

Sienna 的技术平台是基于一个名为端粒酶的生物标记物, 以及可用于检测识别端粒酶的人源端粒酶逆转录酶 (hTERT) 蛋白。

hTERT 蛋白是构成人类端粒酶的蛋白复合物的一部分。端粒酶负责部分的端粒维护, 且被认为是肿瘤细胞回避细胞衰老的一项重要机制。在大多数的情况下, 肿瘤细胞利用增量调节端粒酶以避免细胞老化。报告显示, 端粒酶在多达 90% 的人类上皮癌细胞里皆有增量情形, 因此端粒酶被认为是重要的癌症标志物。2009 年的诺贝尔生理和医学奖即颁给研究端粒酶的诸多科学家, 其中包括 Elizabeth Blackburn。

将此重要且独特的生物标记物应用于癌症诊断是世界首见的创举。Sienna 已经开始销售经美国药监局(FDA)注册、用以检测端粒酶的分析物特定试剂。美国领先的病理化验室已将 Sienna

的试剂应用于其自主开发的膀胱癌检查中。试验证明这有助于提高对低恶性膀胱癌的检测灵敏度，并可降低常规尿细胞检查结果中的不确定性。该技术有望利用多种不同的样本继续进行测试，以检测其他癌症种类。

类别

诊断类：肿瘤诊断

关键技术或领先技术的发展阶段

产品已经上市

合作机会

Sienna 寻求投资合作、提供产品代理分销、技术专利授权方面的机会。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: Sienna Cancer Diagnostics Ltd

Key contact name: Matthew Hoskin

Job title of key contact: Chief Operating Officer

Company website address: www.siennadiagnostics.com.au

Company address: c/o Small Technologies Cluster, 1 Dalmore Drive, Scoresby VIC 3179

The company is Unlisted.

ABOUT THE COMPANY

Sienna is a biotechnology company based in Melbourne, Australia. With the help of their large global clinical networks, Sienna is able to drive the discovery and development of novel IVD (in vitro diagnostic) tests for cancer. Sienna manufactures individual component products for research institutions and pathology laboratories to use in research or in their own laboratory developed tests.

Sienna's experienced and diverse team is responsible for the launch of their first product in 2014 in the USA, the anti-hTERT antibody (SCD-A7).

Sienna plans to commercialise their technology globally, with the major markets of the Americas, Europe and the Asia Pacific region all key targets. A combination of direct sales & support personnel, along with distribution partner arrangements will be utilised within the various countries.

KEY OR LEAD TECHNOLOGY

Sienna's technology platform is based on the biomarker called telomerase, and the hTERT protein by which it can be detected.

The hTERT protein forms part of the protein complex of human telomerase. Telomerase is in part responsible for telomere maintenance and regarded as an important mechanism by which tumour cells evade senescence, which in most cases is achieved by up-regulating telomerase. Telomerase is reported as being up-regulated in ~90% of human epithelial cancer cells, thus being recognised as a remarkable marker for cancer. Telomerase was the subject of the 2009 Nobel Prize in Physiology or Medicine for a group of scientists including Elizabeth Blackburn.

Harnessing this important and unique biomarker for the purpose of cancer diagnosis is a world first. Sienna has begun sales of their FDA-registered Analyte Specific Reagent for the detection of telomerase. Leading pathology laboratories in the USA are performing their own diagnostic tests for bladder cancer using Sienna's reagent. These tests have been shown to improve the sensitivity of low grade bladder cancer detection as well as reduce the frequency of indeterminate findings for standard urine cytology. Further tests for the detection of other cancers in a wide range of sample types are expected to follow.

Category

Diagnostics: Diagnostics oncology

Point of development of key or lead technology

Product on the market

OPPORTUNITIES SOUGHT

Investment partners, distributors, in-licensing opportunities.